PureTech Health PLC PureTech Appoints Bharatt Chowrira as President
March 02 2017 - 2:01AM
RNS Non-Regulatory
TIDMPRTC
PureTech Health PLC
02 March 2017
2 March 2017
PureTech Health plc
PureTech Health Appoints Bharatt Chowrira, Ph.D., J.D., as
President and Chief of Business and Strategy
Biopharmaceutical veteran brings strong track record of value
realisation with multiple billion dollar deals and
collaborations
PureTech Health plc ("PureTech" or the "Company", LSE: PRTC), a
cross-disciplinary biopharmaceutical company, today announced the
appointment of Bharatt Chowrira, Ph.D., J.D., as the Company's
President and Chief of Business and Strategy. In this new role, Dr.
Chowrira will work as a close partner to PureTech's Chief Executive
on strategy, corporate and business development, and value
realisation across PureTech Health's pipeline.
"We are thrilled to have Bharatt join PureTech Health and bring
his diverse experience and deal-making track record to our team as
we rapidly approach key value-driving milestones," said Daphne
Zohar, Chief Executive Officer of PureTech Health.
"PureTech Health has an all-star team and an exciting, advanced
pipeline which I believe has tremendous value. I look forward to
working closely with Daphne and other members of this exceptional
team and prestigious board to realise some of this value and raise
the profile of the company with a broader group of investors and
analysts. This is an exciting time to join one of the most
innovative companies in healthcare and biotech," Dr. Chowrira
commented.
Dr. Chowrira joins PureTech Health with more than two decades of
experience in the biopharma industry, combining a unique blend of
R&D, corporate development, operations, financing, public
offering, M&A, legal, IP, and licensing expertise. Dr. Chowrira
was most recently the President of Synlogic, a Cambridge, MA-based
biopharmaceutical company focused on developing synthetic
microbiome-based therapeutics, where he oversaw and managed
corporate and business development, alliance management, financial,
HR, IP, and legal operations. Prior to joining Synlogic, Dr.
Chowrira was the Chief Operating Officer of Auspex Pharmaceuticals,
which was acquired by Teva Pharmaceuticals in the spring of 2015
for $3.5 billion. Previously, he was President and Chief Executive
Officer of Addex Therapeutics, a biotechnology company
publicly-traded on the SIX Swiss Exchange. Before that, he held
various leadership and management positions at Nektar Therapeutics,
Merck & Co., Sirna Therapeutics (acquired by Merck & Co.
for $1.1 billion), and Ribozyme Pharmaceuticals. Dr. Chowrira also
serves on the board of Critical Outcome Technologies, Inc. He has a
J.D. from the University of Denver's Sturm College of Law, a Ph.D.
in Molecular Biology from the University of Vermont College of
Medicine, an M.S. in Molecular Biology from Illinois State
University, and a B.S. in Microbiology from the UAS, Bangalore,
India.
About PureTech Health
PureTech Health (PureTech Health plc, PRTC.L) is a
cross-disciplinary biopharmaceutical company creating 21(st)
century medicines that modulate the adaptive human systems. Our
therapies target the immune, nervous, and gastro-intestinal systems
by addressing the underlying pathophysiology of disease from a
systems perspective rather than through a single receptor or
pathway. We have multiple human proof-of-concept studies and
pivotal or registration studies expected to read out in the next
two years. PureTech Health's rich and growing research and
development pipeline has been developed in collaboration with some
of the world's leading scientific experts who, along with
PureTech's experienced team and board, analyse more than 650
scientific discoveries per year to identify and advance only the
opportunities we believe hold the most promise for patients. This
team and process place PureTech Health on the cutting edge of
ground-breaking science and technological innovation and leads the
Company between and beyond existing disciplines. For more
information, visit www.puretechhealth.com or connect with us on
Twitter.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
For further information:
PureTech Health FTI Consulting
Allison Mead Ben Atwell
+1 617 651 3156 +44 (0) 20 3727 1000
amead@puretechhealth.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGGGDXDDGBGRD
(END) Dow Jones Newswires
March 02, 2017 02:01 ET (07:01 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024